ArticleJournal of clinical & translational endocrinology2025
Insulin dose adjustment policy for certified diabetes care and education specialists: Safe and effective.
Article in Journal of clinical & translational endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
In 4T Study 1, youth with new-onset type 1 diabetes started a continuous glucose monitor (CGM) soon after diagnosis and received remote CGM data review and dose changes by a Certified Diabetes Care and Education Specialist (CDCES) via secure portal messaging. We describe the CDCES policy to make incremental dose adjustments and report its safety and effectiveness, which facilitated patients' reaching and maintaining targets. We aim to publish this data-supported CDCES protocol to facilitate use at other diabetes centers who may restrict CDCES from adjusting insulin doses. The CDCESs and Pediatric Endocrinologists agreed on criteria for making dose changes. CDCESs made insulin dose adjustments and consulted with Pediatric Endocrinologists per protocol and as needed. CDCES sent messages with suggested dose adjustments and behavior changes via secure portal messaging. In the first year, a total of 1564 remote patient monitoring messages were sent to 133 participants. Most messages were triggered by low time-in-range (TIR, 70-180 mg/dl [63 %]), hypoglycemia (39 %), decline in TIR (13 %), or insufficient CGM wear time (7 %). There were 3 episodes of severe hypoglycemia, none adjudicated related to the CDCES dosing protocol. At one year, the mean time <70 mg/dl was <2 %, and the A1C target of <7 % was met by 64 %. We created a policy for CDCESs to adjust insulin doses and increase patient interaction between visits. The results demonstrate that CDCES can work at the top of their certification to adjust insulin doses to achieve target goals without decreasing safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.